Vitamin D and Ageing: Neurological Issues

Cédric Annweiler\textsuperscript{a, b, d} Anne-Marie Schott\textsuperscript{e, f} Gilles Berrut\textsuperscript{g, h} Valérie Chauviré\textsuperscript{a, c} Didier Le Gall\textsuperscript{b, d} Marco Inzitari\textsuperscript{i} Olivier Beauchet\textsuperscript{a, b, d}

\textsuperscript{a} Angers University Memory Center, and Departments of \textsuperscript{b} Internal Medicine and Geriatrics and \textsuperscript{c} Neurology, Angers University Hospital, and \textsuperscript{d} UPRES EA 2646, University of Angers, UNAM, Angers, \textsuperscript{e} Department of Medical Information, Lyon University Hospital and \textsuperscript{f} University of Lyon, Lyon, and \textsuperscript{g} Department of Geriatrics, Nantes University Hospital, and \textsuperscript{h} University of Nantes, UNAM, Nantes, France; \textsuperscript{i} Socio-Sanitary Hospital Pere Virgili and Institute on Aging of the Autonomous University of Barcelona, Barcelona, Spain

Key Words
Vitamin D \cdot Central nervous system \cdot Life span \cdot Neuro-psychogeriatrics

Abstract
Objective: Vitamin D has been shown to have multiple biological targets mediated by the vitamin D receptor present in many cells. Specific actions on the central nervous system (CNS) have been described. The objective of this review was to describe the relationship between vitamin D and the nervous system throughout the different stages of life. Methods: A bibliographical search was performed in the MedLine and Cochrane library databases. The keywords used were: ‘vitamin D’ and ‘nervous system’ and/or ‘central nervous system’ and/or ‘nervous system diseases’ and/or ‘psychological tests’ and/or ‘neuropsychological tests’ and/or ‘mental disorders’. The search period ranged from 01/01/1988 to 31/10/2009. Two hundred and ninety-five abstracts were first identified after screening. A final selection of 127 articles was used for the purpose of this review. Results: The studies published over the past 20 years provide an increasing number of arguments in favor of a life-long role of vitamin D on the nervous system as a whole, and in particular on the CNS. During cerebral development, vitamin D may act like a neurosteroid hormone in the areas of neurotransmission, neuroprotection, and neuroimmunomodulation. Moreover, vitamin D deficiency has been associated with neurological and psychiatric disorders. In older adults, hypovitaminosis D has been associated with neuromuscular disorders, dementia, and Parkinson’s disease. Thus, vitamin D supplementation might have a protective effect against these neurological disorders. Conclusions: Vitamin D has been associated with many neurological functions and its deficiency with dysfunction. Low serum 25-hydroxyvitamin D concentrations can potentially be reversed. This simple and low-cost correction might contribute to the primo-secondary prevention of various neuropsychiatric disorders.

Copyright © 2010 S. Karger AG, Basel

Introduction
Vitamin D is a secosteroid hormone typically associated with regulation of phosphocalcic homeostasis and osteogenesis [1]. The past decade was characterized by an
increased number of publications which highlighted that vitamin D was not only associated with bone disease, but also with non-bone adverse health outcomes, including immunosuppression, cancer, infections, and cardiovascular diseases [1, 2]. These associations are related to the fact that vitamin D has multiple biological targets mediated by the vitamin D receptor (VDR) present in numerous cells [1].

Vitamin-D-related effects upon the central nervous system (CNS) have been described less than other target organs [1], but it appears that vitamin D deficiency is associated with neurological dysfunction [1, 2]. The objective of this literature review was to describe the relationship between vitamin D and the nervous system throughout the different stages of life.

**Methods**

The bibliographical search consisted of an English and French literature review of the MedLine and Cochrane library databases. The search period ranged from 01/01/1988 to 31/10/2009. The following Medical Subject Headings (MeSH) terms were used: ‘vitamin D’ and ‘nervous system’ and/or ‘central nervous system’ and/or ‘nervous system diseases’ and/or ‘psychological tests’ and/or ‘neuropsychological tests’ and/or ‘mental disorders’. The search also included the reference lists of the retrieved articles. In order to ensure a comprehensive approach, additional key studies known to the authors that did not meet the search criteria were also included. Abstracts identified with the literature search were independently evaluated by 2 reviewers (C.A. and O.B.). Two hundred and ninety-five abstracts were first identified after screening.

Final selection criteria were applied when neurological, mental, or neuropsychological data were used as the outcome, and when a serum 25-hydroxyvitamin D$_2$ (25-OHD$_2$) concentration was provided and/or vitamin D and analog supplementation was used. A final selection of 127 articles was used for the purpose of this review.

**Results**

**Mechanism of Action of Vitamin D**

Vitamin D can be ingested or synthesized in the skin under the action of ultraviolet B (UVB) rays, resulting in a pre-vitamin D going through 2 successive hydroxylations, first in the liver and then in the kidney. Vitamin D can therefore be found in different forms, depending on the degree of hydroxylation: the active form is 1,25-(OH)$_2$D$_3$, its own active form of vitamin D. Vitamin D acts like an auto- or paracrine hormone of the neurosteroid type [11, 12], binding locally to the VDR expressed in the neural network, and the spinal cord [3, 10]. Such metabolic pathways support the role of vitamin D in brain homeostasis. Experimental studies in rodents have confirmed this action.

Vitamin D and Neuro-Ontogenesis

The impact of vitamin D during the natural development of the CNS during the embryonic period has been studied primarily in rodents. VDR develop in the CNS of rats from the 12th day of embryonic development [5]. They appear predominantly in the neuroepithelium in the early stages of neurogenesis, then in the subventricular zone of the lateral ventricles [5], where neural stem cells are found. VDR heterodimerization seems to play a part in the neuro-ontogenetic process. Prenatal vitamin D deficiency is the model of choice to study these implications. McGrath et al. [6] created a Developmental Vitamin D model in rats, and established that the brain of rats born from mothers with a vitamin D deficiency during pregnancy was morphologically modified, with greater length, enlarged lateral ventricles, and a thinner cortex compared to control newborns [7]. In these animals, the mitotic cellular proliferation was significantly increased, the apoptotic phenomena were slowed down [7], and a dysregulation of synaptic plasticity and neurotransmission was observed, caused by the altered expression of 36 brain proteins [7] and mitochondrial disorders [8].

These observations confirm the key role of vitamin D in the regulation of neuroprogenitors, the proliferation and differentiation of the nervous tissue, and the control of the CNS metabolic pathways during embryogenesis.

Vitamin D and Brain: The Bases of a Physiological Relationship

In adults, vitamin D 25-hydroxylase and 25-hydroxyvitamin D-1α-hydroxylase, but also 24-hydroxylase, which degrades 25-OHD$_2$ and 1,25-(OH)$_2$D$_3$, are present in the brain, highlighting that the CNS contains all the enzymatic material required to locally metabolize its own active form of vitamin D. Vitamin D acts like an auto- or paracrine hormone of the neurosteroid type [11, 12], binding locally to the VDR expressed in the neural and glial cells of the temporal, orbital and cingulate cortex, but also in the thalamus, the nucleus accumbens, the stria terminalis, the amygdaloid complex, the olfactory network, and the spinal cord [3, 10]. Such metabolic pathways support the role of vitamin D in brain homeostasis. Experimental studies in rodents have confirmed this action.
Neurotrophic Function and Neurotransmission
Vitamin D has the trophic functions of neuronal differentiation and maturation via control of the neurotrophin levels and the number of mitoses. In vitro, vitamin D increases the synthesis of neurotrophic agents, such as nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin 3 (NT-3), as well as the synthesis of low-affinity p75 NTR receptors; it also accelerates neuronal growth in a dose-dependent manner in rat hippocampal cell cultures [14]. In the opposite way, the synthesis of neurotrophine 4 (NT-4) is slowed down by vitamin D [15]. Moreover, vitamin D plays a part in the regulation of numerous neurotransmitters in rat brain, including acetylcholine, dopamine, serotonin, and γ-aminobutyric acid [1, 11–13].

Neuroprotection
Such neurotrophic qualities make vitamin D a neuroprotective agent. As an example, trophic induction plays a neuroprotective role in cerebral ischemia [16] (table 1), as well as an anti-neurodegenerative role for dopaminergic cells in animal models of Parkinson’s disease [11], and it also prevents neurotrophic deficits in diabetic rats [17].

The neuroprotective effect also results from intraneuronal calcium homeostasis being maintained via the regulation of voltage-dependent calcium channels [11], and via the synthesis of calcium-related cytoplasmic proteins such as parvalbumin or calbindin protein [18]. Moreover, it seems that vitamin D plays a part in the cerebral processes of detoxification by interacting with reactive oxygen and nitrogen species in the rat brain and by regulating the activity of γ-glutamyl transpeptidase [11, 19], a key enzyme in the antioxidative metabolism of glutathione.

Table 1. Key studies showing an association between serum vitamin D concentration or vitamin D supplementation and mental or neurological diseases

<table>
<thead>
<tr>
<th>Field of research</th>
<th>Disease or disorder</th>
<th>Study design</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental diseases</td>
<td>behavior disorders</td>
<td>observational studies</td>
<td>[25–31] low</td>
</tr>
<tr>
<td>schizophrenia</td>
<td>[37, 38] 263 subjects, 38.9 years (13–85 years)</td>
<td>[39] 9,114 subjects, 31 years (supplementation: min. 2,000 IU/day during the first year of life)</td>
<td>[36] moderate</td>
</tr>
<tr>
<td>depression</td>
<td>[32, 37, 43–45] 1,591 subjects, 71.6 years (13–95 years)</td>
<td>[48] 15 subjects, 15–61 years (supplementation: 1 dose of 100,000 IU)</td>
<td>[27, 31] moderate</td>
</tr>
<tr>
<td>Nervous system diseases</td>
<td>epilepsy</td>
<td>observational studies</td>
<td>[23, 55, 56] moderate</td>
</tr>
<tr>
<td>epilepsy</td>
<td>[52] 3 subjects, 0.2 years</td>
<td>[53, 54] 24 subjects, 14.5 years (6–32 years) (supplementation: 4,000 IU/day for 28 days, then 16,000 IU/day for 28 days or 8,000 IU/day for 28 days)</td>
<td>[23, 55, 56] moderate</td>
</tr>
<tr>
<td>multiple sclerosis</td>
<td>[59, 61, 63] 973 subjects, 28.0 years (6–76 years)</td>
<td>[68, 69] 188,117 subjects (25–58 years) (supplementation: dietary intakes)</td>
<td>[57, 58, 64] high</td>
</tr>
<tr>
<td>cerebral tumor</td>
<td>[73] 11 subjects, 54.4 years (49–71 years) (supplementation: 0.04 μg/kg/day)</td>
<td>[70–72, 74–76] low</td>
<td></td>
</tr>
<tr>
<td>cerebral ischemia</td>
<td>[16]</td>
<td></td>
<td>[16] low</td>
</tr>
<tr>
<td>Neurodegenerative diseases</td>
<td>Alzheimer’s disease</td>
<td>observational studies</td>
<td>[109, 110, 114, 115] high</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>[43, 97–103, 105] 4,289 subjects, 77.7 years (60–94 years)</td>
<td>[116] 69 subjects, 84 years (70–89 years) (supplementation: dietary intakes)</td>
<td>[109, 110, 114, 115] high</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>[119–122] 751 subjects, 65.2 years (37–92 years)</td>
<td>[125] 1 subject, 47 years (supplementation: 4,000 IU/day)</td>
<td>[123, 124] low</td>
</tr>
</tbody>
</table>

Numbers of subjects and mean age (range) are calculated from all studied populations.

Vitamin D and the Central Nervous System

Neuropsychobiology 2010;62:139–150
Concentrations of around 0.1–100 nmol 1,25-(OH)_2D_3 thus ensure the efficient protection of neurons against the direct effects of superoxide ions and hydrogen peroxide [20]. Additionally, Garcon et al. [11] demonstrated that vitamin D inhibited the synthesis of inducible nitric oxide synthase, an enzyme produced in CNS cells in response to stress and which in high doses results in neuronal cell death. Finally, the protective properties of vitamin D against mineralization in the human brain should be highlighted [1, 21]. Calcium deposits have been described in the basal ganglia of subjects with normal calcemia and phosphorexia alongside hypovitaminosis D.

Neuroimmunomodulation
VDR-dependent immunosuppressive effects, including increased concentrations of inflammatory cytokines, macrophages, and polymnuclears, as well as their sensitization to apoptotic signals, have been described in the CNS [1]. Vitamin D additionally inhibits the expression of major histocompatibility complex class II proteins and co-factor 4, which play an important part in the autoimmune processes of the nervous system [11]. As an example, in a model of mice with experimental allergic encephalitis (EAE), 1,25-OH_2D_3 inhibited autoimmune neurological processes. However, vitamin D deficiency increased autoimmune damage [19]. Similarly, this effect disappeared in transgenic mice without functional cerebral VDR (or VDR knockout; VDR-KO) [22]; thus, confirming the roles of vitamin D and VDR in neuroimmunomodulation pathways. As such, vitamin D or its analogous agents could be considered as a new anti-inflammatory therapeutic class [1].

These experimental observations underline the central role of vitamin D in controlling the homeostasis of the CNS, from the embryonic period until adulthood. It therefore seems essential to maintain functioning VDR and high serum 25-OHD_2 concentrations throughout life to avoid the occurrence of hypovitaminosis-D-related neurological disorders.

Non-Senile Hypovitaminosis D and Neuropsychopathological Disorders
While vitamin D is essential to the physiological functioning of the nervous system, vitamin D deficiency is associated with severe neurological disorders of various clinical manifestations depending on the nature of the dysfunction induced.

In rodents, the adult VDR-KO mouse model (i.e. deprived of functional VDR) presented with neuromuscular disorders, hypoacusia, and phosphocalcic homeostasis dysregulation associated with thalamic calcifications [21, 24]. Moreover, the absence of VDR in the brain is responsible for behavioral disorders related to anxiety and motor disorders [25–31] (table 1). As an example, grooming did not follow the usual cephalocaudal progression of the wild phenotype; rather, it was anarchically performed by VDR-KO mice, with frequent interruptions and an atypical distribution with more paw grooming [25]. A modification of social behaviors, illustrated by aggression and aberrant maternal behaviors (such as negligence and cannibalism), was also observed [26]. Severe motor disorders, such as a limited ability to swim and reduced movements while swimming, have also been reported [27]; thus, suggesting the essential role of vitamin D in motor control.

In humans, VDR have been described in the cortex, cerebellum, and limbic system, which are key zones for the behavior. The genetic polymorphism of VDR could be responsible for severe psychiatric, neurologic, or neuropsychiatric phenotypes. As such, vitamin D deficiency has long been known to be accompanied by irritability, anxiety, depression, and psychosis [32, 33] (table 1).

Schizophrenia
According to the neurodevelopmental hypothesis of schizophrenia, prenatal vitamin D deficiency could be a risk factor for schizophrenia [6, 12, 33, 34] (table 1). An epidemiological link has been observed between the season of birth, latitude, and the occurrence of schizophrenia [6], with subjects who eventually develop a schizophrenic disorder being born significantly more frequently during winter time, in the higher latitudes of the globe, and in urban zones, i.e. where the maternal serum 25-OHD_2 concentrations (depending on the cutaneous action of solar UVB rays) are lower. Mackay-Sim et al. [35] suggested that low 25-OHD_2 levels during neuroformation could interact with susceptibility genes; thus, modifying the development of the brain through epigenetic regulation and favoring the occurrence of psychosis.

Animal experimentation supports this hypothesis: in schizophrenic rat models as well as in Developmental Vitamin D rat models, reduced frontal and left temporal production of ATP, mitochondrial density, and numbers of coding transcripts for pre-synaptic proteins (such as synapsin-2) were observed [9]. Furthermore, ApoE, which was identified in these Developmental Vitamin D model rats, is now considered a risk factor for schizophrenia. Similarly, Burne et al. [36] demonstrated that chronic pre- and postnatal vitamin D deficiencies in animals,
unlike the deficiency observed in the early days of life, were risk factors for developing schizophrenia.

In humans, low serum 25-OHD$_2$ concentrations have been reported in patients with schizophrenia [37, 38]. Such observations are consistent with the findings of the prospective study of McGrath et al. [39] who described a decreased incident risk of long-term schizophrenic psychosis in 9,114 subjects supplemented with vitamin D over the first year of life.

Depression and Anxiety

An association between vitamin D deficiency and anxiodepressive disorders is likely (table 1). Burne et al. [27] demonstrated a parallel between the behavioral and motor disorders observed in VDR-KO mice and animal models of depression. In humans, various theories have been suggested in order to explain seasonal mood swings. It has recently been suggested that vitamin D, acting on the hypothalamic core (which plays a role in mood regulation [4, 40]), could be the missing link between seasonal changes in photoperiod and seasonal mood swings [41, 42]. Data from epidemiological studies are coherent with such a hypothesis. As an example, Wilkins et al. [43] established that low serum 25-OHD$_2$ concentrations were closely related to active mood disorders in 80 subjects aged 65 years and older living at home. Other authors have also demonstrated that lower serum 25-OHD$_2$ and 1,25-(OH)$_2$D$_3$ concentrations are observed in depressive subjects compared to healthy subjects [33, 44, 45]. This data was indirectly confirmed in around 4,000 women aged 67 years on average by Silverman et al. [46] who established a link between depression and osteoporosis, with a higher risk of developing depression in women with a history of compressed vertebrae compared to women without such history. Nevertheless, this result has to be mitigated and potentially related to physical inactivity and functional impairment, both of which may increase with osteoporosis and have been independently associated with depression. Also, Oren et al. [47] found no significant differences between serum vitamin D concentrations in 15 depressed subjects compared to 15 healthy controls.

Clinical trials support the hypothesis of the efficacy of vitamin D supplementation on mood disorders. As an example, Gloth et al. [48], in a pilot study, administered 100,000 IU of vitamin D to 8 subjects with seasonal depression, while 7 other subjects were treated with phototherapy. Vitamin D was associated with improved depression scale results, while phototherapy was not. However, Dumville et al. [49] did not observe any improvement in SF12 scale scores following 6 months’ vitamin D supplementation (800 IU/day) in 1,621 women aged 70 years and older. It should be noted that the authors did not take into account the initial vitamin D status, which plays a major role in the efficiency of non-bone vitamin D effects, a deficiency being associated with a greater efficacy of supplementation. Furthermore, the daily prescribed vitamin D dose also seems to play a decisive role and should be at least 800 UI. In a prospective trial, Harris and Dawson-Hughes [50] also observed seasonal mood swings in 250 menopausal women, in spite of daily vitamin D supplementation at 400 IU.

Epilepsy

An association between vitamin D deficiency and epilepsy has been postulated (table 1). On the one hand, vitamin D deficiency could be explained by epilepsy treatment as valproate is a cytochrome P450 enzyme inhibitor that could potentially increase the catabolism of 25-OHD$_2$ to inactive metabolites 24,25-dihydroxyvitamin [51]. However, based on the vitamin D neurosteroid regulation role, a scenario of reverse causation is also plausible and should be considered. Thus, in rachitic children, seizures accompanied by low calcium and 25-OHD$_2$ concentrations have been observed [52, 53], whereas long-term vitamin D supplementation led to a reduced incidence of these symptoms [54]. Furthermore, a direct antiepileptic effect of 1,25-(OH)$_2$D$_3$ was reported in mice [23, 55, 56], suggesting a possible control of the regulation of epileptogenic focuses. Moreover, according to Kalueff and Tuohimaa [1], the vitamin-D-supplementation-related increased calcium concentration could lead to a reduced incidence of seizures in epileptic patients.

Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS, the etiology of which could be related to environmental risk factors. Vitamin D deficiency – regulating cell proliferation and differentiation, as well as immunomodulation in the CNS [11–22] – could consequently be considered as a potential risk factor for MS (table 1).

Studying EAE – the animal model of human MS – has provided experimental support for such a hypothesis. Indeed, vitamin D deficiency was responsible for a worsening of symptoms [57], while supplementation could prevent EAE in mice or block its progression with a dose-dependent effect [57, 58]. This effect disappeared
VDR-KO EAE mice; thus highlighting the role of the VDR in the mediation of such action [22].

In humans, there are mainly epidemiological data, as low serum 25-OHD$_2$ concentrations have been associated with a high incidence of MS [59]. A mean 25-OHD$_2$ concentration below 20 ng/ml was described in 48–71% of MS subjects [60]. Furthermore, a 41% increase in the incidence of MS for a 20-ng/ml 25-OHD$_2$ drop was calculated in teenagers in the USA [61]. Moreover, the incidence of MS increases with latitude and decreased sunlight and cutaneous synthesis of vitamin D [62]. The symptomatology of MS is also improved during pregnancy [62], during which 1,25-(OH)$_2$D$_3$ levels are physiologically increased. Also, relapse rates are inversely associated with ambient UVB radiation and serum vitamin D concentrations [63].

In addition, the association of VDR genotypes with MS has been explored in humans [64–66]. While BsmI and ApaI polymorphisms assessed from 77 MS cases and 95 healthy controls showed that the AA genotype and the A allele were significantly more prevalent in cases than in healthy controls, suggesting a risk factor for MS [64], no significant association between the polymorphisms rs11574010 (Cdx-2 A>G), rs10735810 (Fok1 T>C), or rs731236 (Taq1 C>T) and MS risk was observed in 136 MS cases and 235 controls [65]. Furthermore, a study on 212 MS cases and 289 controls showed no association of the Fok1 VDR gene polymorphism with MS [66].

Finally, it has to be noted that no correlation has been found between serum 25-OHD$_2$ and T$_1$ gadolinium-enhancing or T$_2$-weighted MRI lesions [67].

Despite these last negative data, Kampman et al. [68] recently reported a protective effect of the regular consumption of fish or cod liver oil (both high in vitamin D) on MS outcomes. Such results confirm the cohort data gathered from the Nurses’ Health Study I and II, which demonstrated that daily dietary vitamin D intake was responsible for a 40% reduction in the prospective risk of developing MS in almost 200,000 initially healthy women [69].

Cerebral Tumor

Hypovitaminosis D is considered by some authors as a risk factor for tumor (table 1), while its experimental differentiation and antiproliferation properties could actually make vitamin D an antitumor agent [1, 11]. As such, 1,25-(OH)$_2$D$_3$ induced the cellular death of rat glioma cell lines [70–72], and its in vitro efficacy was recently extended to human malignant cell lines [73–76].

Peripheral Neuropathy

Vitamin D status also seems to be associated with the peripheral nervous system as reduced nervous conduction speeds have been reported in women with a vitamin D deficiency [77], whereas the opposite effect was demonstrated after vitamin D and calcium supplementation of a 40-year-old man with idiopathic hypoparathyroidism [78]. Additionally, an improvement in symptomatic peripheral neuropathy was observed with QR-333, a local topical compound containing vitamin D, in 34 subjects with diabetes in a controlled double-blind randomized multicentre trial [79].

Vitamin D therapy might also be useful as a neuroprotective strategy. As the protecting role of vitamin D increases with age [1], supplementation seems particularly useful in deficient elderly, especially as part of management strategies for gait disorders and neuropsychological decline.

Senile Hypovitaminosis D and Neurological Senescence

From an epidemiological viewpoint, vitamin D deficiency is very frequent in older subjects, affecting more than 50% of subjects aged 65 years and older [80]. It has also been proven that vitamin D deficiency is associated with an increased risk of developing age-related diseases [2, 9, 81]. More specifically, a high prevalence of neurological disorders has been observed in these geriatric populations at risk of hypovitaminosis D: neuromuscular disorders and cognitive impairment affect respectively around 60 and 70% of subjects aged 75 years and older [82, 83]. Such observations support the hypothesis of a relationship between ‘senile’ hypovitaminosis D and neurological function impairment in older subjects.

Neuromuscular Function and Gait

Any motor behavior requires adequate motor coordination, and thus requires integrity of the muscular and neurological systems. At the muscular level, vitamin D regulates intramuscular and intramitochondrial calcium concentrations, facilitates excitation coupling, and consequently participates in the good functional equilibrium of type II muscle fibers [84]. Therefore, some authors have suggested that such vitamin-D-induced actions could influence the level of muscular strength in older adults [84, 85]. However, Annweiler et al. [85] recently highlighted the existence of contradictory elements concerning the association between vitamin D and muscular performance in older subjects, both in observational and interventional studies. Nevertheless, vitamin D supple-
Vitamin D and the Central Nervous System

Cognitive Function: Alzheimer’s Disease

More than 10% of people over 65 years and 50% of people over 85 years develop dementia [82]. Alzheimer’s disease (AD) represents 60–70% of these cases [95], and is a chronic neurodegenerative disease with insidious evolution caused by the complex interaction of genetic and environmental factors [95], potentially including hypovitaminosis D (table 1). Epidemiological studies revealed low serum 25-OHD$_2$ concentrations in subjects with AD [43, 96–98]. Wilkins et al. [43] found a significant positive association between serum 25-OHD$_2$ levels and Clinical Dementia Rating/Short Blessed Test scores in 80 older subjects aged 65 years and over, living at home (40 subjects with AD and 40 non-demented subjects). Additionally, Przybelski et al. [99] and Oudshorn et al. [100] highlighted an association with the score obtained on the Mini Mental Status Examination. Similarly, Llewellyn et al. [101] demonstrated in 1,766 non-demented subjects or with mild cognitive impairment (mean age 78 years, 60% women) that the lowest serum vitamin D concentrations matched the highest risk of pathological Abbreviated Mental Test score. Wilkins et al. [102] also found a significant linear association between serum vitamin D concentration and the Short Blessed Test score among 60 elderly non-demented or mild cognitive impairment patients (mean age 75 years). Finally, Annweiler et al. [103] showed a significant positive association (OR = 2.03, p = 0.012) between vitamin D deficiency (25-OHD$_2$ < 10 ng/ml) and a pathological score for Pfeiffer’s Short Portable Mental State Questionnaire among 752 women (mean age 82 years). In contrast, 2 studies found no significant association [32, 104]. First, Jorde et al. [32] unsuccessfully explored the linear association of serum vitamin D with 6 specific cognitive functions (working memory, episodic memory, speed of information processing, language, executive functions, and intelligence) in 148 older subjects with hyperparathyroidism (mean age 62 years, 46% women). Second, McGrath et al. [104] found no significant positive logistic association between the quintiles of serum vitamin D concentrations and several specific cognitive tasks among 4,747 adults aged between 20 and 59 years (symbol-digit substitution coding speed: attention and episodic memory; serial digit learning trials to criterion: working memory). The choice of cognitive outcome appears to be critical, and explains the divergent results. It remains unclear which specific cognitive functions are affected in vitamin D deficiency and explain the link with impaired global composite cognitive scores. We suggest a close association of ‘senile’ hypovitaminosis D with impaired executive functions. Indeed, amongst 1,080 subjects (mean age 75 years, 76% women) free of neuropsychiatric disorders (epilepsy, schizophrenia, bipolar disorder, mental retardation, brain tumors, human immunodeficiency virus), Buell et al. [105] found a significant positive linear association between serum 25-OHD$_2$ concentrations and scores in tests exploring executive functions (trail making test: flexibility) and speed of information processing (digit symbol coding). Finally, an indirect relationship between a low bone mineral density (BMD) in senile osteoporosis – primarily related to vitamin D deficiency – and cognitive decline has been reported [106, 107]. The authors did not specify whether low BMD was related to a recent loss of bone mass, to an early menopause, or to a low bone mass peak. However, Lui et al. [107] demonstrated that older women with rapid bone loss were at a higher risk of cognitive decline than those with a slower bone loss or a growing bone mass, independent of baseline BMD and without these differences being explained by functional status, the use of estrogens, or by ApoE.

From a molecular point of view, 2 proteins connected to the vitamin D system, the calbindin protein and the Klotho protein, have been associated to a reduced number of synapses in the hippocampus and to marked cognitive impairment [106, 108]. Similarly, a significant re-
duction in the number of VDR has been reported in AD [109], and its polymorphism was suggested to be involved in neuronal ageing and neurodegenerative diseases by impairing the neuroprotection and neuroregulation mechanisms of neurotrophic factors and calcium homeostasis [110]. Poduslo and Yin [111] thus demonstrated that 3 markers located near the VDR gene on chromosome 12 were associated with the development of AD. Additionally, Gezen-Ak et al. [110] demonstrated a significant association between VDR gene APA1 polymorphism and the occurrence of AD, with the Aa genotype multiplying the risk of developing AD 2.3-fold compared to the AA genotype. Also in this study, the AATT combined genotype was more often present in healthy controls than in patients with AD, suggesting a protective effect on AD [110]. However, no relationship with FOQ1 or TAQ1 polymorphisms has been observed [110, 112].

Current curative therapeutic strategies for AD primarily aim at fighting neuronal damage, making vitamin D the ideal candidate, with its neurotrophic, neuroprotective, and neurotransmission qualities. Among others, vitamin D is responsible for increased acetylcholine concentrations in rat brain [11], and for reducing in vitro glutamate neurotoxicity and dopaminergic toxins [20]. These detoxification properties seem to be of particular importance, some authors having suggested the central role of oxidative stress in the pathophysiology of neurodegenerative disorders [113]. As an example, there is a probability that detoxification processes are locally altered within hippocampal CA1 and CA2 regions, which play a major part in cognitive processes and are more vulnerable during AD [4, 109, 114]. It has been demonstrated that vitamin D reduces inflammatory disorders and hippocampal degenerative processes in elderly rats, and is also responsible for decreased levels of the biological markers of ageing [10, 114, 115]. In humans, Rondanelli et al. [116] showed a significant reverse correlation between dietary vitamin D intakes and cognitive test performance ($r = 0.24$, $p < 0.05$) in 69 community-dwelling healthy older subjects (mean age 84 years). To the best of our knowledge, no prospective clinical trial has been able to demonstrate the efficacy of vitamin D intake on cognitive function [117].

Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disease affecting the central dopaminergic pathways by damaging neuroprotective processes [118], which hypovitaminosis D in elderly subjects could be responsible for [119–125] (table 1). Vitamin D deficiency was indeed observed in Parkinson’s patients, irrespective of their functional state [119–121]. VDR gene Bsm1 polymorphism was recently associated with PD: the allele b and BB homozygosity having been more frequently observed in subjects with Parkinson’s disease, compared to healthy controls [122].

These observations were confirmed by animal models. The dopaminergic cell degeneration induced by the intraventricular administration of 6-hydroxydopamine in rats made an animal model similar to PD in humans. It was demonstrated that long-term vitamin D supplementation [123, 124] could reduce 6-hydroxydopamine neurotoxicity by increasing the quantity of GDNF in the substantia nigra, but not in the striatum, and by improving hypokinesia and neuronal toxicity.

To the best of our knowledge, in humans, only 1 case report presented an improvement in PD symptoms in a 47-year-old male patient supplemented with calcium and vitamin D at a dose of 4,000 IU daily, following resistance to the usual antiparkinsonian treatment, with persistent improvement at 1 year [125]. Using vitamin D in human PD therefore seems promising, although larger investigations such as an interventional prospective study are required.

Conclusion

An increasing number of elements are in favor of a positive association between vitamin D and neurological status, vitamin D deficiency being associated with neurological disorders. The lack of negative published data can probably be explained by publication bias [126], but also highlight the reliability of the association. Whether in humans or in animals, vitamin D, a neurosteroid hormone, seems to occupy a central place in the regulation of neurotransmission, neuroprotection, neuroimmunomodulation, and cerebral networks and processes throughout life. Motor, psychological, and social behaviors that are adapted to individuals and to the surrounding environment are thereby induced. However, the high prevalence of hypovitaminosis D in the populations of developed countries, and particularly in older adults, seems to play a part in cerebral and neuromus-
cular ageing, along with an alteration of neuronal processes and a deterioration of the functions these processes fulfill. It is now agreed that inadequate vitamin D intake in elderly subjects cannot be effectively handled with dietary measures or food supplementation alone [127]. Such observations might reinforce the pharmacological potential of vitamin D in neuroimmunological and neurodegenerative disease management strategies.

References


45 Hoogenrijk WJ, Lips P, Dik MG, Deeg DJ, Beckman AT, Penninx BW: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008;65:508–512.


Vitamin D and the Central Nervous System


1127 Nowson C: Vitamin D status of Australians: Impact of Changes to Mandatory Fortification of Margarine with Vitamin D. Canberra, Australia and New Zealand Food Authority, 2001.